The DOI matches its Crossref record; 47 of the 53 references it cites were found in a registry or an index.
Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment
Open accessAbstract
Tumor-derived cell lines play an important role in the investigation of tumor biology and genetics. Across a wide array of studies, they have been tools of choice for the discovery of important genes involved in cancer and for the analysis of the cellular pathways that are impaired by diverse oncogenic events. They are also invaluable for screening novel anticancer drugs. The TP53 protein is a major component of multiple pathways that regulate cellular response to various types of stress. Therefore, TP53 status affects the phenotype of tumor cell lines profoundly and must be carefully ascertained for any experimental project. In the present review, we use the 2014 release of the UMD TP53 database to show that TP53 status is still controversial for numerous cell lines, including some widely used lines from the NCI-60 panel. Our analysis clearly confirms that, despite numerous warnings, the misidentification of cell lines is still present as a silent and neglected issue, and that extreme care must be taken when determining the status of p53, because errors may lead to disastrous experimental interpretations. A novel compendium gathering the TP53 status of 2,500 cell lines has been made available (http://p53.fr). A stand-alone application can be used to browse the database and extract pertinent information on cell lines and associated TP53 mutations. It will be updated regularly to minimize any scientific issues associated with the use of misidentified cell lines (http://p53.fr).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, p53 is mutated or altered in multiple immortalized cell lines 62,63 , resulting in altered DDR.”
From AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain (2025) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
PLAQUE FORMATION AND ISOLATION OF PURE LINES WITH POLIOMYELITIS VIRUSES
Dulbecco, R., & Vogt, M. (1954) · The Journal of Experimental Medicine · doi:10.1084/jem.99.2.167 · Cited by 3,837
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppé, J., Tong, F. K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,224
Self-citationThe NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1951 · Cited by 2,673
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
A small-cell lung cancer genome with complex signatures of tobacco exposure
Pleasance, E., Stephens, P. J., O’Meara, S., McBride, D. J., Meynert, A. M., Jones, D., Lin, M., Beare, D. M., Lau, K. W., Greenman, C., et al. (2009) · Nature · doi:10.1038/nature08629 · Cited by 1,076
Self-citationp53 mutations in colorectal cancer.
Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J., & Lane, D. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7555 · Cited by 1,002
(1952) · Cancer Research · Cited by 987
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
p53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810
Signatures of mutation and selection in the cancer genome
Bignell, G. R., Greenman, C. D., Davies, H., Butler, A. P., Edkins, S., Andrews, J. M., Buck, G., Chen, L., Beare, D., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08768 · Cited by 707
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set
Ikediobi, O. N., Davies, H. R., Bignell, G. R., Edkins, S., Stevens, C., O’Meara, S., Santarius, T., Avis, T., Barthorpe, S., Brackenbury, L., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0433 · Cited by 443
Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.
Isaacs, W. B., Carter, B. S., & Ewing, C. M. (1991) · PubMed · Cited by 439
Rae, J. M., Creighton, C. J., Meck, J. M., Haddad, B. R., & Johnson, M. D. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9392-8 · Cited by 374
Cross-contamination of cells in culture
Nelson-Rees, W. A., Daniels, D. W., & Flandermeyer, R. R. (1981) · Science · doi:10.1126/science.6451928 · Cited by 329
Global Proteome Analysis of the NCI-60 Cell Line Panel
Gholami, A. M., Hahne, H., Wu, Z., Auer, F. J., Meng, C., Wilhelm, M., & Kuster, B. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.018 · Cited by 302
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology
Abaan, O. D., Polley, E. C., Davis, S. R., Zhu, Y. J., Bilke, S., Walker, R. L., Pineda, M., Gindin, Y., Jiang, Y., Reinhold, W. C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3342 · Cited by 288
Cell line misidentification: the beginning of the end
American Type Culture Collection Standards Development Organization Workgroup ASN-0002 (2010) · Nature Reviews Cancer · doi:10.1038/nrc2852 · Cited by 266
Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research
Gazdar, A. F., Girard, L., Lockwood, W. W., Lam, W. L., & Minna, J. D. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq279 · Cited by 240
Self-citationMabuchi, S., Altomare, D. A., Cheung, M., Zhang, L., Poulikakos, P. I., Hensley, H. H., Schilder, R. J., Ozols, R. F., & Testa, J. R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2770 · Cited by 234
MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?
Chambers, A. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1528 · Cited by 218
Liscovitch, M., & Ravid, D. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.01.013 · Cited by 152
p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.
Debernardis, D., Siré, E. G., de Feudis, P., Vikhanskaya, F., Valenti, M., Russo, P., Parodi, S., D’Incalci, M., & Broggini, M. (1997) · PubMed · Cited by 146
Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines.
Cottu, P. H., Muzeau, F., Estreicher, A., Fléjou, J., Iggo, R. D., Thomas, G. D., & Hamelin, R. (1996) · PubMed · Cited by 104
Berglind, H., Yudi Pawitan, Y., Kato, S., Ishioka, C., & Soussi, T. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.5.5712 · Cited by 102
Self-citationCell Line Designation Change: Multidrug-Resistant Cell Line in the NCI Anticancer Screen
Scudiero, D. A., Monks, A. P., & Sausville, E. A. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.862 · Cited by 96
Kropveld, A., Rozemuller, E. H., de Straat, F. G. J. L.-V., Scheidel, K. C., de Weger, R. A., Koole, R., Hordijk, G. J., Slootweg, P. J., & Tilanus, M. G. J. (1999) · PubMed · Cited by 90
Drexler, H. G., Fombonne, S., Matsuo, Y., Hu, Z.-B., Hamaguchi, H., & Uphoff, C. (2000) · Leukemia · doi:10.1038/sj.leu.2401604 · Cited by 71
Overexpression and mutations of p53 in metastatic malignant melanomas
Hartmann, A., Blaszyk, H., Cunningham, J. S., McGovern, R. M., Jj, S., Helander, S. D., Pittelkow, M. R., Sommer, S. S., & Kovach, J. S. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960729)67:3 · Cited by 63
Chow, V. T. K., Quek, H. H., & Tock, E. P. C. (1993) · Cancer Letters · doi:10.1016/0304-3835(93)90256-9 · Cited by 59
Hauser, U., Balz, V., Carey, T. E., Grenman, R. A., Lierop, A. V., Scheckenbach, K., & Bier, H. (2002) · Head & Neck · doi:10.1002/hed.10128 · Cited by 48
Christgen, M., & Lehmann, U. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.9.4624 · Cited by 41
Saeki, H., Kitao, H., Yoshinaga, K., Nakanoko, T., Kubo, N., Kakeji, Y., Morita, M., & Maehara, Y. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1996 · Cited by 40
Comment Re: MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?
Hollestelle, A., & Schutte, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2396 · Cited by 38
Self-citationRecommendations for Analyzing and ReportingTP53Gene Variants in the High-Throughput Sequencing Era
Soussi, T., Leroy, B., & Taschner, P. E. M. (2014) · Human Mutation · doi:10.1002/humu.22561 · Cited by 37
Self-citationThe DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53
Bajgelman, M. C., & Strauss, B. E. (2006) · The Prostate · doi:10.1002/pros.20462 · Cited by 36
Suwa, H., Yoshimura, T., Yamaguchi, N., Kanehira, K., Manabe, T., Imamura, M., Hiai, H., & Fukumoto, M. (1994) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1994.tb02898.x · Cited by 32
Detecting p53 Isoforms at Protein Level
Marcel, V., Khoury, M. P., Fernandes, K., Diot, A., Lane, D. P., & Bourdon, J.-C. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-236-0_2 · Cited by 22
Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines
Murai, Y., Hayashi, S., Takahashi, H., Tsuneyama, K., & Takano, Y. (2005) · Pathology - Research and Practice · doi:10.1016/j.prp.2005.01.002 · Cited by 22
Detecting and Quantifying p53 Isoforms at mRNA Level in Cell Lines and Tissues
Khoury, M. P., Marcel, V., Fernandes, K., Diot, A., Lane, D. P., & Bourdon, J. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-236-0_1 · Cited by 20
Persistent use of misidentified cell lines and its prevention
MacLeod, R. A. F., Dirks, W. G., & Drexler, H. G. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1217 · Cited by 20
Soussi, T. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.07.003 · Cited by 20
Self-citationŠmardová, J., Pavlová, Š., Svitáková, M., Grochová, D., & Ravčuková, B. (2005) · Oncology Reports · doi:10.3892/or.14.4.901 · Cited by 18
Wistuba, I. I., Syed, S., Behrens, C., Duong, M., Milchgrub, S., Muller, C. Y., Jagirdar, J. S., & Gazdar, A. F. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1999.5485 · Cited by 17
Self-citationTichý, A., Záškodová, D., Pejchal, J., Řezáčová, M., Österreicher, J., Vávrová, J., & Cerman, J. (2008) · International Journal of Radiation Biology · doi:10.1080/09553000802078404 · Cited by 10
Cited by
Sorted by citations
Autophagy in malignant transformation and cancer progression
Galluzzi, L., Pietrocola, F., Bravo‐San Pedro, J. M., Amaravadi, R. K., Baehrecke, E. H., Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D. A., Karantza, V., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490784 · Cited by 1,182
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Knijnenburg, T., Wang, L., Zimmermann, M. T., Chambwe, N., Gao, G. F., Cherniack, A. D., Fan, H., Shen, H., Way, G. P., Greene, C. S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.076 · Cited by 1,145
Ki-67: more than a proliferation marker
Sun, X., & Kaufman, P. D. (2018) · Chromosoma · doi:10.1007/s00412-018-0659-8 · Cited by 963
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Leroy, B., Anderson, M., & Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22552 · Cited by 422
Self-citationMolina, D. M., & Nordlund, P. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103715 · Cited by 301
Metadata
- Authors
- Leroy, B., Girard, L., Hollestelle, A., Minna, J. D., Gazdar, A. F., & Soussi, T.
- Affiliations
- Université Pierre-et-Marie-Curie (FR)
- The University of Texas Southwestern Medical Center (US)
- Erasmus MC Cancer Institute (NL)
- Karolinska Institutet (SE)
- Corresponding author
- Soussi, Thierry
- Venue
- Human Mutation
- Publisher
- Wiley
- Published
- 2014-05-06
- Volume
- 35
- Issue
- 6
- Pages
- 756-765
- ISSN
- 1059-7794 (ISSN-L)
- PMC
- PMC4451114
- OpenAlex
- W2030503662
- Cited by
- 224
- References
- 53
- Citations by year
- 2026: 6 · 2025: 20 · 2024: 16 · 2023: 20 · 2022: 29 · 2021: 25 · 2020: 40 · 2019: 20 · 2018: 18 · 2017: 15 · 2016: 3 · 2015: 7 · 2014: 4
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Mutation (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Funders
- National Cancer Institute (P50CA070907)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- TP53 mutation status, cancer cell lines, cell line misidentification, p53, anticancer drug screening
- MeSH terms
- Humans, Mutation, Neoplasms, Software, Tumor Suppressor Protein p53, Internet, Databases, Genetic, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
